RxDoctor Payments DataLook up a doctor →

Bobby Kakati, MD

Gastroenterology · Little Rock, ARNPI 1124252960

Payments from drug & device makers

$13,639in general payments, 2019–2025

Across 832 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Gilead$600
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$550
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$13,639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,639 in reported general payments places this provider in the 75th percentile of 108 gastroenterology providers in Arkansas.

See all gastroenterology providers in Arkansas

Medicare billing

Part B allowed, 2024
$143,115
Medicare patients
318
Services billed
4,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$336,458
XifaxanRifaximin21$66,563
Mesalamine27$10,331
ClenpiqSod Picosulf/Mag Ox/Citric Ac24$4,094
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag21$2,507
Pantoprazole Sodium209$2,172
Omeprazole194$1,808
Sucralfate67$1,628
Colestipol Hcl17$1,200
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl67$906
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl37$651
Famotidine11$4

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$550$66,56321 claims
Ferring Pharmaceuticals Inc.Clenpiq$192$4,09424 claims
Braintree Laboratories, Inc.Suflave$23$2,50721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 108 gastroenterology providers in Arkansas.

Other gastroenterology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →